Media coverage about Dendreon (NASDAQ:DNDN) has been trending somewhat positive recently, Accern reports. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dendreon earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 44.4987976287346 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Dendreon (DNDN) Share Price” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/07/21/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-dendreon-dndn-share-price.html.

About Dendreon

Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company’s product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers.

Receive News & Ratings for Dendreon Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dendreon Co. and related companies with MarketBeat.com's FREE daily email newsletter.